endometrial hyperplasia
Conditions
Interventions
A:Lactobacillus capsules for vagina+dydrogesterone tablets +metformin tablets
???:dydrogesterone tablets +metformin tablets
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Aged <=45 years old; 2. Endometrial sampling under hysteroscope for pathological diagnosis of endometrial hyperplasia (EH); Note: The patient underwent hysteroscopic surgery due to abnormal uterine bleeding (AUB), previous history of EH, or thickened endometrium on ultrasound; 3. Sign informed consent; 4. The patient agrees to the treatment and has good compliance and can be followed up and re-intimal pathology examination.
Exclusion criteria
Exclusion criteria: 1. Diagnosis of endometrial atypical hyperplasia or endometrioid adenocarcinoma by pathological biopsy at the beginning or after treatment, and consultation with a pathologist; 2. Combined with serious medical diseases: cerebrovascular disease, coronary heart disease, diabetes, high blood pressure, obesity, severe fatty liver, severe hyperlipidemia, renal impairment, adrenal hypofunction; 3. Those with an increased risk of arterial or venous thromboembolism, stroke, and myocardial infarction; including women who are known to have the following conditions: 1) Smoking; 2) Deep vein thrombosis or pulmonary embolism present or in the past; 3) Thrombotic valvular heart disease or thrombotic heart rhythm disease (such as subacute bacterial endocarditis with valvular disease or atrial fibrillation); 4) Inherited or acquired hypercoagulable disease; 5) Headache with focal neurological symptoms; or migraine with or without aura; 4. Undiagnosed abnormal uterine bleeding; 5. Current or past breast cancer or other estrogen or progesterone sensitive cancers, combined with other types of endometrial cancer or other malignant tumors of the reproductive system; 6. There may be multiple cancers and repeated cancer tendencies (breast cancer, ovarian cancer), Lynch syndrome, and Cowden syndrome in the family genetic history; 7. Liver benign or malignant tumors or liver diseases including hepatitis; 8. Pregnancy; 9. Allergic to the active ingredients of this product or any of its excipients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission, CR; | — |
Secondary
| Measure | Time frame |
|---|---|
| abnormal uterine bleeding, AUB;Pregnancy related index;16S rRNA gene amplicon sequencing and lactobacillus subtype sequencing of endometrial tissue;Sex hormones;Metabolic index;Immunohistochemistry;effect evaluation; | — |
Countries
China
Contacts
Public ContactYe Yang
Shanghai General Hospital
Outcome results
None listed